Quoin Pharmaceuticals, Ltd. (FRA:2EB0)
Germany · Delayed Price · Currency is EUR | Market Cap | 17.25M +174.3% |
| Revenue (ttm) | n/a |
| Net Income | -16.34M |
| EPS | -7.60 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24 |
| Open | 3.220 |
| Previous Close | 3.180 |
| Day's Range | 3.220 - 3.380 |
| 52-Week Range | 2.800 - 19.300 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic ... [Read more]
News
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient – Patient...
Quoin Pharmaceuticals initiated with a Buy at Canaccord
Canaccord initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $18 price target The firm says rare dermatology remains an attractive place for a biotech company given the…
Quoin’s QRX003 granted Orphan Drug Designation in Europe
Quoin Pharmaceuticals (QNRX) announces that its lead product candidate QRX003 has been granted Orphan Drug Designation in Europe by the European Medicines Agency, or EMA, for the treatment of Peeling…
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin S...
Quoin Pharmaceuticals initiated with a Buy at BTIG
BTIG initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $14 price target Quoin is developing QRX003 for Netherton Syndrome, notes the analyst, who see QRX003’s broad kallikrein…
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome Case Report Details Professor Alan Irvine's Clinical Experience Treating a Pediatric Patient Under Quoin's Compa...
Quoin Pharmaceuticals Proxy statement: Proxy filing
Quoin Pharmaceuticals filed a proxy statement on October 2, 2026, providing details for shareholder voting and corporate governance matters.
Quoin Pharmaceuticals initiated with a Buy at Lake Street
Lake Street analyst Thomas Flaten initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $20 price target QRX003, Quoin’s topical kallikrein inhibitor, is the most clinically advance...
Quoin Pharmaceuticals announces U.S. FDA granted FTD to QRX003
Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to QRX003 for the treatment of Peeling Skin Syndrome, PSS. QRX003 is…
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation Facili...
Quoin Pharmaceuticals Proxy statement: Proxy filing
Quoin Pharmaceuticals filed a proxy statement on September 22, 2026, providing details for shareholder voting and corporate governance matters.
Quoin Pharmaceuticals registers to sell 9.37M ADRs for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 9.37M American depositary shares. The company is not selling any shares…
Quoin Pharmaceuticals Registration statement: Registration filing
Quoin Pharmaceuticals filed a registration statement on September 18, 2026, providing details about a securities offering with the SEC.
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
Quoin Pharmaceuticals releases a new NETHERTON NOW video featuring Laura Wright-Sexton, MD, who first met her daughter Aminah as a patient in the ICU.
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Sk...
Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003
Quoin Pharmaceuticals (QNRX) announced that the FDA has granted Rare Pediatric Disease Designation for the company’s lead asset, QRX003, for the treatment of Peeling Skin Syndrome.
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Sk...
Quoin Pharmaceuticals announces $50M private placement
Quoin Pharmaceuticals (QNRX) announced that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to approximately $50M in gr...
Quoin Pharmaceuticals reports ‘positive’ data from Phase 2/3 study of QRX003
Quoin Pharmaceuticals (QNRX) announced positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome. The primary endpoint of 1-grade...
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participant...
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...
Quoin Pharmaceuticals reports Q2 EPS ($1.90), consensus ($1.77)
“The second quarter was a highly productive period across both of our delivery technology platforms,” said Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals (QNRX). “Our I...
Quoin Pharmaceuticals Earnings release: Q2 2026
Quoin Pharmaceuticals released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Quoin Pharmaceuticals Quarterly report: Q2 2026
Quoin Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 14, 2026.
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Nethe...